Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Trizivir

TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9

HOS-108561 · Präparat HOS-093047

8 Stavudine/Zidovudine In vitro antagonism of anti-HIV activity between stavudine and zidovudine could result in decreased efficacy of both drugs. ANTI-INFECTIVE PRODUCTS Atovaquone/Abacavir Interaction not studied. As only limited data available Atovaquone/Lamivudine Interaction not studied. the clinical significance is Atovaquone/Zidovudine Zidovudine AUC 33% unknown. (750 mg twice daily with Atovaquone AUC  food/200 mg thrice daily) Clarithromycin/Abacavir Interaction not studied. Separate administration of Clarithromycin/Lamivudine Interaction not studied. Trizivir and clarithromycin by Clarithromycin/Zidovudine Zidovudine AUC 12% at least 2 hours (500 mg twice daily/100 mg every 4 hours) Trimethoprim/sulfamethoxazole Interaction not studied. No Trizivir dosage adjustment (Co-trimoxazole)/Abacavir necessary, unless patient has Trimethoprim/sulfamethoxazole Lamivudine: AUC 40% renal impairment (See Section (Co-trimoxazole)/Lamivudine 4.2). (160mg/800mg once daily for 5 Trimethoprim: AUC  days/300mg single dose) Sulfamethoxazole: AUC  When concomitant administration with co- (organic cation transporter trimoxazole is warranted, inhibition) patients should be monitored Trimethoprim/sulfamethoxazole Interaction not studied. clinically. High doses of (Co-trimoxazole)/Zidovudine trimethoprim/ sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (PCP) and toxoplasmosis have not been studied and should be avoided.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) atovaquone (HOS-086266) trimethoprim (HOS-085184) stavudine (HOS-088080) clarithromycin (HOS-084517)